Phil Nadeau
Stock Analyst at TD Cowen
(2.74)
# 1,804
Out of 5,154 analysts
25
Total ratings
45.83%
Success rate
32.11%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Buy | $175 → $215 | $184.87 | +16.30% | 7 | Feb 9, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $175 → $200 | $128.13 | +56.09% | 1 | Dec 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $50 → $45 | $20.07 | +124.22% | 1 | Oct 31, 2025 | |
| KURA Kura Oncology | Reiterates: Buy | n/a | $8.96 | - | 1 | Nov 21, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $93.52 | -30.50% | 2 | Nov 6, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $61.12 | +96.34% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $456.69 | +9.48% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $29.44 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $18.15 | - | 1 | Jul 7, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $5.60 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.16 | - | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.95 | - | 1 | Jul 16, 2018 |
Biogen
Feb 9, 2026
Maintains: Buy
Price Target: $175 → $215
Current: $184.87
Upside: +16.30%
Neurocrine Biosciences
Dec 5, 2025
Maintains: Buy
Price Target: $175 → $200
Current: $128.13
Upside: +56.09%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $50 → $45
Current: $20.07
Upside: +124.22%
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $8.96
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $93.52
Upside: -30.50%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $61.12
Upside: +96.34%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $456.69
Upside: +9.48%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $29.44
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $18.15
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.60
Upside: -
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.16
Upside: -
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $6.95
Upside: -